Company Overview
Vyome Holdings, Inc. operates as a clinical-stage specialty pharmaceutical company focused on developing therapeutic products designed to target immuno-inflammatory and rare diseases within the United States market. The enterprise functions within the Healthcare sector, specifically the Biotechnology industry, a classification that typically denotes entities engaged in the discovery and development of biological agents and pharmaceutical compounds rather than manufacturing or distribution. As of the latest reporting period, the company maintains a total market capitalization of $14.95M and generates annual revenue of $319,714, supported by a workforce of 9 employees. These specific valuation and revenue figures indicate that Vyome Holdings, Inc. is a micro-cap entity with a very small operational scale, reflecting its status as an early-stage biotechnology firm where significant resources are often directed toward research and development rather than broad commercial sales. The minimal employee count relative to the sector suggests a lean organizational structure typical of clinical-stage companies that are prioritizing product pipeline advancement over extensive infrastructure.
Financial Health
The company reported revenue of $319,714 over the trailing twelve months, while simultaneously recording a net income of $-10,262,007 and an EBITDA of $-2,735,052, revealing a substantial disparity between top-line generation and bottom-line profitability. This wide gap between revenue and net income highlights a cost structure characterized by extremely high operating expenses, likely driven by research, development, and clinical trial costs inherent to the biotechnology lifecycle, which result in a negative profit margin of 0.0%. Despite the negative earnings and EBITDA, the company demonstrates positive financial flexibility with free cash flow of $5.11M, a figure bolstered by a cash balance of $4.98M which provides liquidity to fund ongoing operations without immediate external financing. In terms of leverage, the company holds total debt of $31,258 against a cash position of $4.98M, resulting in a debt-to-equity ratio of 0.83, which indicates a balance sheet that is technically leveraged but heavily cash-funded rather than burdened by interest obligations. The current ratio stands at 1.99, suggesting that the company possesses strong short-term liquidity with current assets nearly double its current liabilities, ensuring it can meet immediate financial obligations. Return on Equity is listed as N/A due to the lack of positive retained earnings, while Return on Assets is -43.6%, indicating that for every dollar of assets employed, the company currently generates a negative return, a common metric for pre-revenue or clinical-stage biotechnology firms.
Valuation Assessment
The trailing P/E ratio is N/A because the company has not generated positive net income over the trailing twelve months, while the forward P/E is also N/A, implying that the market cannot value the stock based on earnings multiples due to the absence of current profitability. The price-to-book ratio is recorded at 5.16, which indicates that the stock is trading at a significant premium over its book value, a valuation characteristic often seen in biotechnology stocks where future pipeline potential is priced in rather than current asset value. Alternative valuation metrics such as the price-to-sales ratio of 46.76 and the EV/EBITDA of -4.14 suggest that investors are pricing the company based on revenue generation and cash position rather than earnings power, reflecting high expectations for future commercial success from its product candidates. The stock's price range over the last year fluctuated between a 52-week low of $1.75 and a 52-week high of $305.00, placing the current trading price in a wide range that reflects high historical volatility typical of small-cap biotechnology equities. The beta value is N/A, meaning that standard volatility metrics relative to the broader market are not available or applicable for this specific security in the provided data.
Growth & Income
Revenue growth year-over-year is reported at -40.5%, while earnings growth is N/A due to the company's continued lack of profitability, indicating that the business is currently in a contraction phase or a period of heavy investment where revenue has not yet scaled to cover costs. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings, though currently negative, are theoretically retained for reinvestment into research and development rather than distribution to shareholders. This non-dividend profile is consistent with clinical-stage specialty pharmaceutical companies that must prioritize capital allocation toward advancing their lead product candidate, VT-1953, and other therapeutic products targeting immuno-inflammatory and rare diseases. The overall growth and income profile of Vyome Holdings, Inc. is defined by negative revenue momentum and a complete absence of dividend income, positioning the security as a pure speculative play on future clinical outcomes rather than a source of current income or stable growth.